Clinical Trial Update: Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer

View source ↗

Summary

A clinical trial evaluating FES-PET and FDG-PET for predicting response to hormone therapy in estrogen receptor-positive metastatic breast cancer was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Metastatic Breast Cancer | Status: TERMINATED